Health Canada Approves MedMira's Rapid HIV Test for Point-of-Care Use

MedMira Inc. has received approval from Health Canada for its Reveal® G4 Rapid HIV-1/2 Test, designed for Point-of-Care use. This test boasts a sensitivity of 99.64% and specificity of 99.71%, making it a reliable choice for healthcare providers. It provides immediate results by detecting HIV-1/2 antibodies using a simple finger prick.

The test leverages MedMira’s patented Rapid Vertical Flow Technology®, ensuring accurate results without special storage requirements. The integration of a procedural control line assures users of correct test performance, crucial for accurate HIV diagnoses.

With an increase of over 35% in new HIV diagnoses in Canada from 2022 to 2023, MedMira aims to support healthcare efforts with innovative, accessible diagnostics. This approval follows the recent approval of MedMira’s Multiplo® TP/HIV test as the company expands its product offerings for diverse healthcare needs.